GPCR
Structure TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes successful clinical readouts, one or more strategic partnerships, and meaningful uptake of lead oral GPCR-targeted therapy, driving re-rating toward peers and multiples seen in commercial-stage specialty biotech.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Capital raise dilution
Momentum
7
Value
41
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $32.00 · Bull $45.00 · Bear $18.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $108.93
Why
Momentum7 · Δ7d +1.9
Value41 · Δ7d +0.1
Sentiment38 · Δ7d +4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
7
34% active weight
Current posture
7d trendFlat
Δ7d
+1.9
Δ21d
+3.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
38
33% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+6.5
Why this grade
Composite grade F. Momentum 6.8 / Value 41.1 / Sentiment 37.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.74B
Beta
-
Shares Out
182.03M
P/E (TTM) · Derived
-6.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.42
Rev YoY
-
EPS YoY
-89.2%
Gross Margin
-
Op Margin
-
Net Debt
-$883.52M
Current Ratio
14.15
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology